Xenetic Biosciences, Inc.
No SEC Form 4 filings for $XBIO in the last 30 days.
See all $XBIO insider activity →Xenetic Biosciences (XBIO) announced the first patient was dosed in a study combining its DNase I with approved anti-CD19 CAR T therapies for LBCL. The trial, led by investigators in Israel, aims to report initial efficacy data by Q2 2027, according to the company.
Xenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026 2 This communication contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform
Xenetic Biosciences (XBIO) will merge with private Santersus AG in an all-stock deal, creating a Nasdaq-listed company focused on NET-targeting therapies. Existing XBIO shareholders will own 15% of the combined entity, named Santersus Bio (SNTS), while Santersus shareholders get 85%. The merger, expected to close in Q4 2026, combines four clinical programs, including two with FDA Breakthrough Device Designation. The combined company will be led by Santersus CEO James Ladtkow.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning XBIO (Xenetic Biosciences, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent XBIO coverage spans financial news, corporate actions and earnings.
The first patient dose is a positive catalyst that could drive the stock higher as efficacy data emerge.
The merger announcement is likely to drive significant volatility in XBIO as investors price the deal premium and integration risks.
The merger will dilute existing XBIO shareholders to ~15% and shift control to Santersus owners, likely pressuring XBIO's share price.
The merger is likely to trigger a price gap for XBIO as the market prices the all‑stock transaction and the creation of the new ticker.
The print is modestly positive on recurring royalty momentum and preclinical translational progress, but the cash burn and higher G&A tied to a strategic review keep risk elevated.
AlphAI scores every news story that mentions XBIO with an AI model for sentiment and relevance, and aggregates insider trades from Xenetic Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Xenetic Biosciences (XBIO) announced the first patient was dosed in a study combining its DNase I with approved anti-CD19 CAR T therapies for LBCL. The trial, led by investigators in Israel, aims to report initial efficacy data by Q2 2027, according to the company.
2 min readXenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026 2 This communication contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform
1 min readXenetic Biosciences (XBIO) will merge with private Santersus AG in an all-stock deal, creating a Nasdaq-listed company focused on NET-targeting therapies. Existing XBIO shareholders will own 15% of the combined entity, named Santersus Bio (SNTS), while Santersus shareholders get 85%. The merger, expected to close in Q4 2026, combines four clinical programs, including two with FDA Breakthrough Device Designation. The combined company will be led by Santersus CEO James Ladtkow.
2 min readXenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellul
2 min readXenetic Biosciences (NASDAQ:XBIO) reported Q2 2026 results for the quarter ended June 30. Royalty revenue rose about 12% to about $0.7M, while R&D fell about 16% to about $0.6M. G&A increased about 64% to about $1.1M, driving a net loss of about $0.9M. Cash was about $6.5M. The company cited ASCO preclinical/translational data and a PeriNess study approval.
4 min readXenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform Expanded collaborative research initiatives reinforce the Company's long-term DNase deve
2 min readXenetic Biosciences, Inc. has extended its collaboration with The Scripps Research Institute and Dr. Alexey Stepanov for an additional four months to further develop its DNase platform. This collaboration focuses on advancing Xenetic's systemic DNase I candidate, XBIO-015, in combination with CAR T-cell therapies for various cancers, building on preclinical studies that showed significant improvements in reducing tumor burden and extending survival. The company is progressing its DNase-based technology towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.
3 min readWhile daily stock price moves tend to dominate headlines, shifts in fundamental ranking scores can often tell a deeper story about a company's trajectory. This week, Benzinga's proprietary Growth, Value, Quality and Momentum data revealed major swings among several popular stocks, from biotech to ...
4 min readXenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readFRAMINGHAM, MA / ACCESS Newswire / May 14, 2025 / Xenetic Biosciences, Inc. ( NASDAQ:XBIO ) ( "Xenetic" or the "Company" ) , a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for ...
3 min read
